Nanjing Norman Biological Technology Co., Ltd., founded in 2008, is a comprehensive medical technology enterprise integrating R&D, manufacturing, marketing, and service. The company provides full‑lifecycle healthcare solutions and advanced diagnostic and medical device procurement services to major hospitals and healthcare institutions worldwide.

      Norman holds over 140 authorized intellectual property rights and has been recognized as a National High‑Tech Enterprise and a National Specialized and Innovative "Little Giant" Enterprise. The company has received honors such as Jiangsu Provincial Engineering Technology Center, Jiangsu Provincial Enterprise Technology Center, Jiangsu Science and Technology Progress Award, and was selected as a Nanjing Unicorn Cultivation Enterprise. Norman also serves as a Postdoctoral Innovation Practice Base and an internship/employment base for Nanjing University.

Innovation & R&D Capability：

      Adhering to the philosophy that "R&D determines the future, focus ensures success," Norman has built a mature, integrated innovation system centered on three product lines: Clinical IVD Diagnostics, Home Health & Anti‑Aging Products, and Clinical Medical Instruments & Therapeutic Devices.

      The company operates dedicated departments for IVD raw materials, reagent development, instrument engineering, and regulatory affairs, ensuring end‑to‑end innovation capabilities from core components to finished devices. The Upstream IVD Raw Material Department independently develops and manufactures key inputs such as antigens, antibodies, and magnetic beads, and maintains an SPF‑grade animal facility.

      Norman’s independently developed procalcitonin (PCT) antibody has obtained international patent authorization (European Patent No. EP16820699.3; U.S. Patent No. US 10,882,900 B2), providing a solid foundation for product traceability and overcoming critical technical bottlenecks in the IVD industry. To accelerate medical‑engineering integration and technology translation, the company has established a Medical‑Engineering Innovation Center to collaborate with domestic and international universities and top teaching hospitals, supported by dedicated funds for commercialization.

Market Presence：

      Domestically, Norman’s products are deployed in over 30% of China’s top‑tier (Class III Grade A) hospitals, with strong applications and reputation in pediatric respiratory infections, myocardial injury and heart failure, thrombosis, and oncology testing.

      Internationally, approximately 180 Norman products have obtained CE certification and are exported to countries including Germany, Italy, and Bulgaria, as well as more than 30 regions across the Middle East, Southeast Asia, South America, and Africa. The company is actively establishing local subsidiaries in the Philippines and Indonesia to strengthen its global footprint.

Mission & Core Values：

      Guided by the core value of "Customer First," Norman fosters a culture of self‑driven and self‑reflective talent, with technological innovation as its lifeblood and human health as its mission. The company is committed to delivering more comprehensive and reliable healthcare solutions worldwide. Through continuous innovation and clinical collaboration, Norman aims to make advanced medical technologies widely accessible and to make meaningful contributions to global health, striving to be a trusted global medical‑health technology company.